Clinical Connection

This trial is not actively recruiting.

This trial has completed recruitment on this platform, and is no longer accepting new referrals.

SGN35-028: A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL) or peripheral T cell lymphoma (PTCL)

A retreatment study with brentuximab vedotin in subjects with classical Hodgkin lymphoma or peripheral T cell lymphoma whose cancer got better after taking brentuximab vedotin, and subsequently got worse. USM/BVM/2021/0037

Trial ID: NCT03947255

Trial Details

We want to learn if the study drug brentuximab vedotin can be used to retreat complete response (CR) or partial response (PR) patients with classic Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma(sALCL) or Pripheral T cell lymphoma (PTCL).

Subjects enrolled would be treated every 3 weeks and Subjects may continue on treatment until disease progresses, unacceptable side effects, or study closure occurs.

Estimated Enrollment

80 Participants

Phase

2

Eligibility Criteria

Participants must:
  • 18yrs or older
  • Have been diagnosed with Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma
  • Have previously received treatment with brentuximab vedotin, (ADCETRIS) and the cancer got better
  • 6 months of improvement before patient was told that their cancer had progressed (gotten worse) or had returned
Participants must not:
  • Previously discontinued brentuximab vedotin due to any Grade 3 or higher toxicity
  • Existing Grade 2 or higher peripheral neuropathy
  • Previously did not respond (improve) with treatment of brentuximab vedotin or responded (improved) but the duration of response was less than 6 months after taking Brentuximab Vedotin
  • Active cerebral/meningeal disease

What Will Happen in This Study

If you choose to take part in this study, your doctor will review your medical history, conduct a physical examination and do tests to see if you can be in the study. If you can be in the study and choose to take part, we will do tests to see if brentuximab vedotin can affect your disease. If your cancer stays the same or gets better, and you don’t have any serious problems, you can keep getting brentuximab vedotin.

You will need to travel to one of the study clinics taking part in this clinical trial.

Sites are located in the cities/states identified with the red pin:

Frequently Asked Questions (FAQs)